This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
models was 100 years (with 1-year cycles). The health states considered in the models were no disease, acute stage, indeterminate stage, general chronic stage, cardiomyopathy with chronic heart failure (CHF), cardiomyopathy without CHF, and two death states (one due to CHD and one due to all other causes). Patients were allowed to stay only a maximum of 1 year in the acute stage. Patients stayed a minimum of 10 years in the indeterminate stage before being allowed to progress to the chronic stage.
Outcomes assessed in the review
The outcomes assessed were: the CHD age-specific incidence and the CHD mean annual incidence with and without vector control; the decrease in incidence due to vector control programmes; the mortality rates due to all causes and to CHD; and the transition probabilities between the health states considered in the model.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
At least 11 studies were included in the review.
Methods of combining primary studies
A narrative method was used to combine the primary studies.
Investigation of differences between primary studies
Results of the review
There were too many clinical and epidemiological parameters to report in this abstract. The only value that will be reported here is the decrease in incidence due to vector control programmes, which was 70% (range: 70 to 90).
Estimates of effectiveness and key assumptions
The authors assumed that the prevalence of acute CHD was 0.00001. They also assumed that 20% of patients who were in the megaviscera stage would have palliative surgery at some point and either improve or die. Death from megaviscera was assumed to occur as a surgical or post-surgical death only. Moreover, some patients might remain in the indeterminate stage for life, but the model assumed that eventually everyone would move to the chronic phase, and/or eventually die of either CHD related or other causes. Finally, it was assumed that a new potential drug treatment would cure 50% of patients at the indeterminate or mild chronic stage.
Measure of benefits used in the economic analysis
The summary measure of health benefits used was the quality-adjusted life-years (QALY) saved. Disability weights obtained from the literature were used to adjust the life-years gained (life expectancy) for the loss of quality of life due to the time with disease. The health benefits were discounted at a rate of 3%.
Direct costs
The costs were discounted at a rate of 3%. The costs and the quantities of resource used were not presented separately. The treatment costs were obtained from a study performed in Argentina and were divided by disease stage. The acute phase included medical consultation, general laboratory tests, parasitologic and conventional serologic tests for T-cruzi infection, drug treatment (benznidazole), electrocardiograms, chest radiographs and hepatograms. The indeterminate stage included periodic medical visits, laboratory testing, radiographs and electrocardiograms. The chronic phase included diagnosis and supportive treatment weighted according to the prevalence of the type and severity of symptoms.
The costs of vector programmes were obtained from the literature. Only data for the Southern Cone region of LA were available; the authors assumed the same cost for the other two regions. The cost of a potential new drug treatment was estimated, assuming a 6-month course of treatment given once per infected person. The authors determined a cost for a course of treatment based on currently available treatments for CHD, and estimated what the market would probably be willing to pay. It was assumed that all patients in the indeterminate and early chronic stages would receive drug treatment.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The authors did not evaluate productivity costs separately since they included these work losses as part of the quality of life adjustments.
